TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator-controlled Study Evaluating the Efficacy and Safety of Guselkumab for the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis With Randomized Withdrawal and Retreatment
Brief Summary: The purpose of this study is to evaluate the efficacy, safety, and tolerability of guselkumab (CNTO 1959) in the treatment of participants with moderate to severe plaque-type psoriasis (scaly skin rash).


Options:
A: Arm Label: Placebo Comparator: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Voclosporin 0.2 mg/kg po BID; Type: ACTIVE_COMPARATOR; Interventions: Drug: voclosporin | Arm Label: Voclosporin 0.3 mg/kg po BID; Type: ACTIVE_COMPARATOR; Interventions: Drug: voclosporin | Arm Label: Voclosporin 0.4 mg/kg po BID; Type: ACTIVE_COMPARATOR; Interventions: Drug: voclosporin | Intervention Type: DRUG; Name: voclosporin; Assigned to Arm(s): Voclosporin 0.2 mg/kg po BID, Voclosporin 0.3 mg/kg po BID, Voclosporin 0.4 mg/kg po BID | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Comparator: 1
B: Arm Label: Apremilast 10mg; Type: EXPERIMENTAL; Interventions: Drug: Apremilast 10mg | Arm Label: Apremilast 20mg; Type: EXPERIMENTAL; Interventions: Drug: Apremilast 20mg | Arm Label: Apremilast 30 mg; Type: EXPERIMENTAL; Interventions: Drug: Apremilast 30 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Placebo/Apremilast 20 mg; Type: EXPERIMENTAL; Interventions: Drug: Apremilast 20mg | Arm Label: Placebo/Apremilast 30mg; Type: EXPERIMENTAL; Interventions: Drug: Apremilast 30mg | Intervention Type: DRUG; Name: Apremilast 10mg; Assigned to Arm(s): Apremilast 10mg | Intervention Type: DRUG; Name: Apremilast 20mg; Assigned to Arm(s): Apremilast 20mg | Intervention Type: DRUG; Name: Apremilast 30 mg; Assigned to Arm(s): Apremilast 30 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Apremilast 30mg; Assigned to Arm(s): Placebo/Apremilast 30mg | Intervention Type: DRUG; Name: Apremilast 20mg; Assigned to Arm(s): Placebo/Apremilast 20 mg
C: Intervention Type: DRUG; Name: TNF-alpha antagonists; Assigned to Arm(s): N/A
D: Arm Label: Group I; Type: EXPERIMENTAL; Interventions: Drug: Guselkumab 100 mg, Drug: Placebo for guselkumab, Drug: Placebo for adalimumab | Arm Label: Group II; Type: PLACEBO_COMPARATOR; Interventions: Drug: Guselkumab 100 mg, Drug: Placebo for guselkumab, Drug: Placebo for adalimumab | Arm Label: Group III; Type: ACTIVE_COMPARATOR; Interventions: Drug: Guselkumab 100 mg, Drug: Placebo for guselkumab, Drug: Adalimumab | Intervention Type: DRUG; Name: Guselkumab 100 mg; Assigned to Arm(s): Group I, Group II, Group III | Intervention Type: DRUG; Name: Placebo for guselkumab; Assigned to Arm(s): Group I, Group II, Group III | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): Group III | Intervention Type: DRUG; Name: Placebo for adalimumab; Assigned to Arm(s): Group I, Group II

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3 Randomized, Double-Blind, Placebo-controlled Study in Older Subjects to Assess Safety and the Reversal of Apixaban Anticoagulation With Intravenously Administered Andexanet Alfa
Brief Summary: The purpose of this stuy is to evaluate the ability of Andexanet Alfa to reverse the anticoagulation effect of Apixaban.


Options:
A: Arm Label: Idrabiotaparinux; Type: EXPERIMENTAL; Interventions: Drug: Idrabiotaparinux sodium, Drug: Avidin, Drug: Placebo (for Avidin) | Arm Label: Idraparinux; Type: ACTIVE_COMPARATOR; Interventions: Drug: Idraparinux sodium, Drug: Placebo (for Avidin) | Intervention Type: DRUG; Name: Idrabiotaparinux sodium; Assigned to Arm(s): Idrabiotaparinux | Intervention Type: DRUG; Name: Idraparinux sodium; Assigned to Arm(s): Idraparinux | Intervention Type: DRUG; Name: Avidin; Assigned to Arm(s): Idrabiotaparinux | Intervention Type: DRUG; Name: Placebo (for Avidin); Assigned to Arm(s): Idrabiotaparinux, Idraparinux
B: Arm Label: Andexanet; Type: EXPERIMENTAL; Interventions: Biological: Andexanet | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: BIOLOGICAL; Name: Andexanet; Assigned to Arm(s): Andexanet | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: SR34006 (idraparinux sodium) Injection; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: SR34006; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: (LMW)heparin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Warfarin VKA; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Acenocoumarol VKA; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Contralesional Repetitive Magnetic Stimulation Combined With Fluoxetine on Motor Recovery in Acute Stroke Patients
Brief Summary: In this study investigator's aim to assess the effect of a type of non-invasive brain stimulation technique called repetitive transcranial magnetic stimulation (rTMS) in conjunction with fluoxetine on motor recovery after stroke.


Options:
A: Arm Label: escitalopram; Type: EXPERIMENTAL; Interventions: Drug: Escitalopram | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: sugar pill | Intervention Type: DRUG; Name: Escitalopram; Assigned to Arm(s): escitalopram | Intervention Type: DRUG; Name: sugar pill; Assigned to Arm(s): placebo
B: Arm Label: Active rTMS/active fluoxetine; Type: EXPERIMENTAL; Interventions: Device: Active Repetitive Transcranial Magnetic Stimulation (rTMS), Drug: Fluoxetine | Arm Label: Sham rTMS/active fluoxetine; Type: EXPERIMENTAL; Interventions: Drug: Fluoxetine, Device: Sham repetitive transcranial magnetic stimulation (rTMS) | Arm Label: Sham rTMS/placebo fluoxetine; Type: EXPERIMENTAL; Interventions: Device: Sham repetitive transcranial magnetic stimulation (rTMS), Drug: Placebo Fluoxetine | Intervention Type: DEVICE; Name: Active Repetitive Transcranial Magnetic Stimulation (rTMS); Assigned to Arm(s): Active rTMS/active fluoxetine | Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): Active rTMS/active fluoxetine, Sham rTMS/active fluoxetine | Intervention Type: DEVICE; Name: Sham repetitive transcranial magnetic stimulation (rTMS); Assigned to Arm(s): Sham rTMS/active fluoxetine, Sham rTMS/placebo fluoxetine | Intervention Type: DRUG; Name: Placebo Fluoxetine; Assigned to Arm(s): Sham rTMS/placebo fluoxetine
C: Arm Label: SSRI; Type: EXPERIMENTAL; Interventions: Drug: SSRI | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: SSRI; Assigned to Arm(s): SSRI | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Fluoxetine; Type: EXPERIMENTAL; Interventions: Drug: Fluoxetine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): Fluoxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Unlike the first generation antiepileptic medications, newer drugs for epilepsy such as levetiracetam are reported to have less adverse effect in children but not many studies have systematically reviewed the subject. This study aims to prospectively evaluate the effect of levetiracetam on neurocognition, behavioral issues and quality of life, as well as its seizure control efficacy and other adverse events in pediatric epilepsy patients, in comparison to carbamazepine, one of the classic antiepileptic medication, widely prescribed for both partial and generalized seizures, despite its well known side effects.

This multicenter, open-label, parallel-group trial is expected to enroll 130 patients from age 4 to 16 woh will be randomized into two groups, which will be prescribed with levetiracetam or carbamazepine. Series of neuropsychological assessment and behavioral and life evaluations of the patients will be performed at baseline period and after the 52 weeks of study period.


Options:
A: Arm Label: Zonisamide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Zonisamide | Arm Label: Carbamazepine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbamazepine | Intervention Type: DRUG; Name: Zonisamide; Assigned to Arm(s): Zonisamide | Intervention Type: DRUG; Name: Carbamazepine; Assigned to Arm(s): Carbamazepine
B: Arm Label: Levetiracetam; Type: EXPERIMENTAL; Interventions: Drug: Levetiracetam | Arm Label: Carabamazepine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carabamazepine | Intervention Type: DRUG; Name: Levetiracetam; Assigned to Arm(s): Levetiracetam | Intervention Type: DRUG; Name: Carabamazepine; Assigned to Arm(s): Carabamazepine
C: Arm Label: Keppra XR 1000 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Keppra XR | Arm Label: Keppra XR 2000 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Keppra XR | Intervention Type: DRUG; Name: Keppra XR; Assigned to Arm(s): Keppra XR 1000 mg/day | Intervention Type: DRUG; Name: Keppra XR; Assigned to Arm(s): Keppra XR 2000 mg/day
D: Intervention Type: DRUG; Name: phenobarbitone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: carbamazepine; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Unlike the first generation antiepileptic medications, newer drugs for epilepsy such as levetiracetam are reported to have less adverse effect in children but not many studies have systematically reviewed the subject. This study aims to prospectively evaluate the effect of levetiracetam on neurocognition, behavioral issues and quality of life, as well as its seizure control efficacy and other adverse events in pediatric epilepsy patients, in comparison to carbamazepine, one of the classic antiepileptic medication, widely prescribed for both partial and generalized seizures, despite its well known side effects.

This multicenter, open-label, parallel-group trial is expected to enroll 130 patients from age 4 to 16 woh will be randomized into two groups, which will be prescribed with levetiracetam or carbamazepine. Series of neuropsychological assessment and behavioral and life evaluations of the patients will be performed at baseline period and after the 52 weeks of study period.


Options:
A: Arm Label: Zonisamide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Zonisamide | Arm Label: Carbamazepine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbamazepine | Intervention Type: DRUG; Name: Zonisamide; Assigned to Arm(s): Zonisamide | Intervention Type: DRUG; Name: Carbamazepine; Assigned to Arm(s): Carbamazepine
B: Intervention Type: DRUG; Name: topiramate, phenytoin; Assigned to Arm(s): N/A
C: Arm Label: Levetiracetam; Type: EXPERIMENTAL; Interventions: Drug: Levetiracetam | Arm Label: Carabamazepine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carabamazepine | Intervention Type: DRUG; Name: Levetiracetam; Assigned to Arm(s): Levetiracetam | Intervention Type: DRUG; Name: Carabamazepine; Assigned to Arm(s): Carabamazepine
D: Arm Label: Keppra XR 1000 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Keppra XR | Arm Label: Keppra XR 2000 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Keppra XR | Intervention Type: DRUG; Name: Keppra XR; Assigned to Arm(s): Keppra XR 1000 mg/day | Intervention Type: DRUG; Name: Keppra XR; Assigned to Arm(s): Keppra XR 2000 mg/day

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Unlike the first generation antiepileptic medications, newer drugs for epilepsy such as levetiracetam are reported to have less adverse effect in children but not many studies have systematically reviewed the subject. This study aims to prospectively evaluate the effect of levetiracetam on neurocognition, behavioral issues and quality of life, as well as its seizure control efficacy and other adverse events in pediatric epilepsy patients, in comparison to carbamazepine, one of the classic antiepileptic medication, widely prescribed for both partial and generalized seizures, despite its well known side effects.

This multicenter, open-label, parallel-group trial is expected to enroll 130 patients from age 4 to 16 woh will be randomized into two groups, which will be prescribed with levetiracetam or carbamazepine. Series of neuropsychological assessment and behavioral and life evaluations of the patients will be performed at baseline period and after the 52 weeks of study period.


Options:
A: Arm Label: Healthy control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Carbamazepine group; Type: EXPERIMENTAL; Interventions: Drug: Carbamazepine | Arm Label: Oxcarbazepine group; Type: EXPERIMENTAL; Interventions: Drug: Oxcarbazepine | Intervention Type: DRUG; Name: Carbamazepine; Assigned to Arm(s): Carbamazepine group | Intervention Type: DRUG; Name: Oxcarbazepine; Assigned to Arm(s): Oxcarbazepine group
B: Arm Label: Levetiracetam; Type: EXPERIMENTAL; Interventions: Drug: Levetiracetam | Arm Label: Carabamazepine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carabamazepine | Intervention Type: DRUG; Name: Levetiracetam; Assigned to Arm(s): Levetiracetam | Intervention Type: DRUG; Name: Carabamazepine; Assigned to Arm(s): Carabamazepine
C: Arm Label: Levetiracetam; Type: ACTIVE_COMPARATOR; Interventions: Drug: Levetiracetam | Arm Label: Carbamazepine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbamazepine | Arm Label: Lamotrigine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lamotrigine | Intervention Type: DRUG; Name: Levetiracetam; Assigned to Arm(s): Levetiracetam | Intervention Type: DRUG; Name: Carbamazepine; Assigned to Arm(s): Carbamazepine | Intervention Type: DRUG; Name: Lamotrigine; Assigned to Arm(s): Lamotrigine
D: Arm Label: Keppra XR 1000 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Keppra XR | Arm Label: Keppra XR 2000 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Keppra XR | Intervention Type: DRUG; Name: Keppra XR; Assigned to Arm(s): Keppra XR 1000 mg/day | Intervention Type: DRUG; Name: Keppra XR; Assigned to Arm(s): Keppra XR 2000 mg/day

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Energetic, a Self Management Group Program Aimed at Reconditioning and Social Participation in Persons With a Muscle Disease; a Multicentre Randomized Controlled Trial.
Brief Summary: Fatigue is present in at least 60% of the patients with a muscle disease and can be the most disabling symptom. In combination with other impairments, this often results in low levels of physical activity and decreased social participation, leading to large societal costs. Energetic is a self-management group program aimed at improving participation and physical endurance in these patients. Our hypothesis is that Energetic results in improved participation and improved physical endurance, less experienced fatigue and better quality of life compared to usual care, without increasing health care costs.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Educational session to promote physical activity | Arm Label: 2; Type: OTHER; Interventions: Other: Minimal contact | Intervention Type: OTHER; Name: Educational session to promote physical activity; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Minimal contact; Assigned to Arm(s): 2
B: Arm Label: Standard Care Counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Standard Care Counseling | Arm Label: Supervised Exercise and Counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Supervised Exercise and Counseling | Intervention Type: BEHAVIORAL; Name: Standard Care Counseling; Assigned to Arm(s): Standard Care Counseling | Intervention Type: BEHAVIORAL; Name: Supervised Exercise and Counseling; Assigned to Arm(s): Supervised Exercise and Counseling
C: Arm Label: Behavioural change intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioural change intervention | Arm Label: Standard Patient Management; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Behavioural change intervention; Assigned to Arm(s): Behavioural change intervention
D: Arm Label: Energetic; Type: EXPERIMENTAL; Interventions: Behavioral: Energetic | Arm Label: Control group; Type: OTHER; Interventions: Other: Control group | Intervention Type: BEHAVIORAL; Name: Energetic; Assigned to Arm(s): Energetic | Intervention Type: OTHER; Name: Control group; Assigned to Arm(s): Control group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Energetic, a Self Management Group Program Aimed at Reconditioning and Social Participation in Persons With a Muscle Disease; a Multicentre Randomized Controlled Trial.
Brief Summary: Fatigue is present in at least 60% of the patients with a muscle disease and can be the most disabling symptom. In combination with other impairments, this often results in low levels of physical activity and decreased social participation, leading to large societal costs. Energetic is a self-management group program aimed at improving participation and physical endurance in these patients. Our hypothesis is that Energetic results in improved participation and improved physical endurance, less experienced fatigue and better quality of life compared to usual care, without increasing health care costs.


Options:
A: Arm Label: Exercise; Type: EXPERIMENTAL; Interventions: Other: Exercise on a cycle-ergometer | Arm Label: Controls; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Exercise on a cycle-ergometer; Assigned to Arm(s): Exercise
B: Arm Label: active rehabilitation; Type: ACTIVE_COMPARATOR; Interventions: Other: Active rehabilitation | Arm Label: conventional care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Active rehabilitation; Assigned to Arm(s): active rehabilitation
C: Arm Label: Energetic; Type: EXPERIMENTAL; Interventions: Behavioral: Energetic | Arm Label: Control group; Type: OTHER; Interventions: Other: Control group | Intervention Type: BEHAVIORAL; Name: Energetic; Assigned to Arm(s): Energetic | Intervention Type: OTHER; Name: Control group; Assigned to Arm(s): Control group
D: Arm Label: Behavioural change intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioural change intervention | Arm Label: Standard Patient Management; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Behavioural change intervention; Assigned to Arm(s): Behavioural change intervention

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Department of Traditional Chinese Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung
Brief Summary: Intradialytic hypotension (IDH) is a most frequent complication of hemodialysis (HD) and may contribute to cardiovascular events and high mortality. The etiology of IDH is multifactorial; therefore, it remains a challenging problem in the management of HD patients. Because moxibustion (MO) at specific points can influences hemodynamics, we hypothesize that Tianjiu (auto-MO) at the traditionally used meridian points will reduce the severity of hypotension in patients who undergo HD.


Options:
A: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Energy conservation education intervention for people with end-stage kidney disease receiving hemodialysis | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Energy conservation education intervention for people with end-stage kidney disease receiving hemodialysis; Assigned to Arm(s): Intervention
B: Arm Label: Active; Type: ACTIVE_COMPARATOR; Interventions: Drug: darbepoetin alfa | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: darbepoetin alfa; Assigned to Arm(s): Active
C: Arm Label: CBT-I; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive Behavioral Therapy for Insomnia | Arm Label: Medication- Trazodone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Trazodone | Arm Label: Medication- Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy for Insomnia; Assigned to Arm(s): CBT-I | Intervention Type: DRUG; Name: Trazodone; Assigned to Arm(s): Medication- Trazodone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Medication- Placebo
D: Arm Label: Tianjiu (auto-moxibustion); Type: EXPERIMENTAL; Interventions: Other: Tianjiu | Arm Label: Non-Tianjiu (Non auto-MO); Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo (non-Tianjiu) | Intervention Type: OTHER; Name: Tianjiu; Assigned to Arm(s): Tianjiu (auto-moxibustion) | Intervention Type: OTHER; Name: Placebo (non-Tianjiu); Assigned to Arm(s): Non-Tianjiu (Non auto-MO)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The purpose of this study is to determine whether tDCS in combination with motor training can improve hand and arm function in stroke patients.


Options:
A: Arm Label: Upper limb motor function training + tDCS; Type: ACTIVE_COMPARATOR; Interventions: Device: transcranial direct current stimulation (tDCS) | Arm Label: upper limb motor function training + sham tDCS; Type: SHAM_COMPARATOR; Interventions: Device: transcranial direct current stimulation (tDCS) | Intervention Type: DEVICE; Name: transcranial direct current stimulation (tDCS); Assigned to Arm(s): Upper limb motor function training + tDCS, upper limb motor function training + sham tDCS
B: Arm Label: Rehabilitation training; Type: EXPERIMENTAL; Interventions: Other: Rehabilitation | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Rehabilitation; Assigned to Arm(s): Rehabilitation training
C: Arm Label: Anodal tDCS; Type: EXPERIMENTAL; Interventions: Device: Anodal transcranial direct current stimulation | Arm Label: Cathodal tDCS; Type: EXPERIMENTAL; Interventions: Device: Cathodal transcranial direct current stimulation | Arm Label: Bilateral tDCS; Type: EXPERIMENTAL; Interventions: Device: Bilateral transcranial direct current stimulation | Arm Label: Sham tDCS; Type: SHAM_COMPARATOR; Interventions: Device: Sham transcranial direct current stimulation | Intervention Type: DEVICE; Name: Anodal transcranial direct current stimulation; Assigned to Arm(s): Anodal tDCS | Intervention Type: DEVICE; Name: Cathodal transcranial direct current stimulation; Assigned to Arm(s): Cathodal tDCS | Intervention Type: DEVICE; Name: Bilateral transcranial direct current stimulation; Assigned to Arm(s): Bilateral tDCS | Intervention Type: DEVICE; Name: Sham transcranial direct current stimulation; Assigned to Arm(s): Sham tDCS
D: Arm Label: Device-assisted therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Device-assisted therapy | Arm Label: Therapy-based occupational therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Therapy-based occupational therapy | Intervention Type: BEHAVIORAL; Name: Device-assisted therapy; Assigned to Arm(s): Device-assisted therapy | Intervention Type: BEHAVIORAL; Name: Therapy-based occupational therapy; Assigned to Arm(s): Therapy-based occupational therapy

Answer: A